Healthcare

Valion Bio appoints Armand Balboni as advisor as Entolimod study advances

Valion Bio said Armand Balboni will advise on scientific strategy, medical countermeasures and government and industry partnerships as Entolimod advances through a therapeutic efficacy study.

Published:
Reading Time
3 min

Valion Bio, Inc. (NASDAQ:VBIO) has appointed Armand Balboni, JD, MD, PhD, as an advisor on scientific strategy and medical countermeasure development. The company said his work will centre on Entolimod, its lead medical countermeasure candidate, as a therapeutic efficacy study examines outcomes following radiation exposure.

#Advisor to focus on Entolimod and partnerships

Valion Bio said Dr. Balboni will help shape its scientific approach to Entolimod and support efforts to develop government and industry partnerships. The company described the appointment as bringing together experience in drug development, regulatory affairs, military medicine and strategic collaboration.

Entolimod is being studied for survival and gastrointestinal recovery after radiation exposure. Valion Bio did not provide a date for the study's data readout in the announcement.

#Balboni’s biotechnology and military background

Dr. Balboni previously served as chief executive officer of Appili Therapeutics Inc., where he was responsible for corporate strategy, clinical development and regulatory work. His tenure included oversight of a 1,500-patient Phase 3 trial assessing an antiviral treatment for COVID-19.

He also spent 24 years in the U.S. military and held senior roles within the U.S. Army. His responsibilities included work involving FDA-regulated trials, regulatory submissions, emergency use authorisations and the assessment and procurement of medical technologies for military requirements.

Dr. Balboni served as deputy director of the U.S. Army’s Office of Regulated Activities and completed a Department of Defense fellowship at the FDA. He also worked at the U.S. Army Medical Research Institute of Infectious Diseases, where he directed technology transfer and collaborations involving universities, government agencies and biotechnology and pharmaceutical companies.

#Entolimod’s regulatory position

Valion Bio is developing Entolimod as a potential medical countermeasure for Acute Radiation Syndrome, radiation-induced neutropenia and other indications. The company holds an exclusive, worldwide licence from Statera Biopharma covering development and commercialisation of the candidate for those uses.

The company said Entolimod has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration. Its development is being conducted under the FDA’s Animal Rule, which can permit approval based on animal efficacy studies when human trials are not ethical or feasible.

Valion Bio describes Entolimod as a Toll-like Receptor 5 agonist intended to activate signalling associated with cellular protection, tissue recovery and immune response.

#Additional pipeline and manufacturing operations

Valion Bio is also advancing Entolasta, a next-generation TLR5 agonist designed for potential broader applications, including oncology supportive care. The company’s pipeline includes potential programmes in neutropenia and immune dysfunction.

Its wholly owned subsidiary, Velocity Bioworks, operates as a biologics contract development and manufacturing organisation with mammalian and microbial capabilities. Valion Bio said the subsidiary is focused on manufacturing control, costs, development timelines and domestic supply-chain security.

#Risks and uncertainties

Valion Bio cautioned that statements concerning trial timing and results, Entolimod’s regulatory progress, government interactions, Entolasta, additional capital and continued listing on the Nasdaq Capital Market are subject to substantial risks and uncertainties. The company said actual results could differ from its forward-looking statements and referred readers to its filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 30, 2026.

#Key Takeaways

  • Valion Bio appointed Armand Balboni, JD, MD, PhD, as an advisor on scientific strategy and medical countermeasure development.
  • His responsibilities will include work on Entolimod and government and industry partnerships.
  • Entolimod is undergoing a therapeutic efficacy study evaluating survival and gastrointestinal recovery after radiation exposure.
  • The candidate has Fast Track and Orphan Drug designations and is being developed under the FDA’s Animal Rule.
  • Valion Bio said future development, regulatory and financing outcomes remain subject to substantial risks and uncertainties.

Original source: Read original article

Frequently Asked Questions